Table 2 Changes in clinical measurements

Average dose of QTP (mg/day)

-

379.6 (231.7)

418.5 (243.4)

438.6 (261.7)

-

-

Weight (kg)

56.9 (12.2)

57.6 (12.4)

57.0 (11.6)

57.3 (10.7)

F(3,75) = 0.44

0.64

HbA1C (%)

4.97 (0.32)

4.95 (0.37)

4.98 (0.35)

4.89 (0.32)

F(3,75) = 1.32

0.28

PANSS

Positive symptoms

18.1 (4.7)

15.7 (4.8)

16.4 (54.2)

15.3 (4.1)

F(3,81) = 5.35

<0.01

Negative symptoms

23.5 (5.2)

21.5 (5.5)

20.8 (6.2)

19.6 (6.5)

F(3,81) = 11.40

<0.01

General pathological symptoms

39.8 (10.2)

36.8 (9.3)

36.8 (10.5)

34.7 (10.1)

F(3,81) = 7.83

<0.01

GAF

42.4 (14.7)

50.3 (12.7)

51.7 (14.0)

51.6 (15.6)

F(3,75) = 10.54

<0.01

AIS

5.0 (3.1)

4.9 (3.6)

3.5 (2.9)

3.7 (3.0)

F(3,75) = 3.35

0.04

DIEPSS

6.4 (4.9)

3.9 (3.2)

3.1 (2.8)

3.0 (2.9)

F(3,81) = 13.74

<0.01

Prolactin (ng/ml)

33.1 (26.2)

17.8 (20.8)

21.0 (27.0)

19.9 (28.0)

F(3,69) = 4.04

0.02

DAI-30

−8.6 (3.2)

−5.0 (7.1)

−6.8 (5.2)

−6.3 (5.9)

F(3,69) = 2.78

0.07

JSQLS

Psychosocial

37.9 (13.5)

37.2 (11.7)

35.0 (11.6)

35.3 (12.2)

F(3,66) = 1.42

0.25

Motivation

21.6 (2.9)

20.2 (4.0)

19.9 (2.8)

19.7 (3.6)

F(3,66) = 2.23

0.11

Symptoms and side effects

16.7 (4.5)

14.7 (4.3)

14.4 (4.6)

14.9 (5.4)

F(3,66) = 3.20

<0.05